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Benign Metastasizing Leiomyoma with Multiple Lymph
Node Metastasis: A Case Report
Introduction
Uterine leiomyomas are the most common benign gynecological
tumor of women of reproductive age. Rarely, it shows unusual
growth patterns with associated extrauterine smooth muscle deposits
that seem to be derived from a benign uterine leiomyoma (benign
metastasizing leiomyoma, BML). Hendrickson and Kempson [1]
defined BML as a muscle tumor in association with one or more
smooth muscle tumors of the uterus and without evidence of any
extrauterine primary site. The risk factors, related etiology and
clinical behaviors have been poorly studied. Lung is known to be
the most common metastatic site. Pulmonary metastases are usually
detected by chest radiographs, years after hysterectomy [2]. Except
for lung, the extrauterine sites that these tumors can localize to are
skin, pelvis, abdomen, muscle, greater omentum, inferior vena cava,
right atrium, brain and bones [3]. However, multiple metastases to
lymph nodes in BML are rare and studies about prognosis and
treatment of BML with multiple lymph node metastasis are few.
Here, we report a case of multiple BML in the lymph nodes.
Clinical considerations are discussed.
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This is a case report about benign metastasizing leiomyoma with multiple lymph node
metastasis. A 34-year-old woman received an abdominal myomectomy for a suspicious
leiomyoma. On the pathology report, atypical leiomyoma was suspected. Due to the
suspicion of multiple lymph node metastasis on pelvis computed tomography (CT) 1 year
after the operation, she was transferred to the Samsung Medical Center on October, 2009 for
further work up. According to original slide review, it was determined to be a benign
leiomyoma with a mitotic count ģ5/10 high-power fields, little cytological atypia and no tu-
mor cell necrosis. Additional immunostaining was done. Multiple lymph node metastasis and
a small lung nodule were identified on positron emission tomogarphy-CT and chest CT. Ex-
tensive debulking surgery and diagnostic video-assisted thoracoscopic surgery (VATS)
wedge resection were subsequently done. Metastatic lesions were reported to have a
histology similar to that of the original mass. VATS right upper lobectomy with mediastinal
lymph node dissection was performed because of the pathology result of VATS
(adenocarcinoma). She started taking an aromatase inhibitor (Letrozole
®) and there was no
evidence of recurrence of disease on an imaging study and no post-operative complications
until recently.
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A 34-year-old women with no medical history (parity 1-0-0-1;
normal spontaneous vaginal delivery at 2001, never a smoker)
received an abdominal myomectomy for a palpable 8 cm abdominal
mass with suspicion of leiomyoma by ultrasonography at a local
clinic in July 2008. On pathology, it was found to be suspicious of
cellular myoma or a smooth muscle tumor with uncertain malignant
potential. She was then referred to the nearby university hospital. On
pathology review, she was diagnosed as having a mitotically active
leiomyoma and malignant potential. Due a suspicion of multiple
lymph node metastases on pelvis computed tomography (CT) 1 year
after the operation, she was transferred to the Samsung Medical
Center (October 2009) for further work up. On pelvis CT, there was
enlargement of multiple lymph nodes around the iliac chain and
aorta. An original pathology slide review (Fig. 1) and positron
emission tomogarphy (PET)-CT were done. According to the
original slide review, it was a benign leiomyoma with a mitotic
count ģ5/10 high-power fields (HPF), little cytological atypia and
no tumor cell necrosis. Additional immunostaining indicated that
smooth muscle actin and desmin were positive and CD10 was
negative in the tumor cells. Tumor markers (TA-4, cancer antigen
[CA]-125, CA-19-9, carcinoembryonic antigen) marked all normal.
Abnormal fluorodeoxyglucose uptakes with the suspicion of para-
aortic, aortocaval, precaval, external iliac lymph node and uterine
body metastases were found on PET-CT. Incidentally, a 9 mm
ground-glass opacity lesion at the right apical lung showed faint
FDG uptake. Adenocarcinoma with bronchioloalveolar carcinoma
rather than metastatic leiomyoma was suspected. An additional
chest CT also revealed it to be a primary lung cancer. In December
2009 extensive debulking surgery including total abdominal
hysterectomy, bilateral salpingo-oophorectomy, pelvic and para-
aortic lymph node dissection to the level of the left renal vein, and
gonadal lymph node dissection were done. Grossly, there were no
definite mass-forming lesions in the uterus, and all the lymph nodes
stated above were palpable and enlarged to about 2 to 3 cm in size.
Pathology for an ill-defined residual intrauterine lesion was also a
benign leiomyoma with mitosis ģ5/10 HPF, little cytological atypia
and no tumor necrosis. Metastases to meso-ovarium/salpinx, pelvic
lymph node, inferior mesenteric artery lymph node, para-aortic lymph
node (Fig. 2), gonadal vein and to the parametrium were confirmed
on the final pathology report. Metastatic lesions were also reported
to have similar histology with the original mass with a mitotic count
ģ2/10 HPF, little cytological atypism and no necrosis. Clinico-
pathologically, BML was selected as a final diagnosis with dis-
cussion with our pathologists (COS and GHA). On immuno-
histochemical staining, cells were all positive for estrogen/pro-
gesterone receptors. Video-assisted thoracoscopic surgery right up-
per lobectomy with mediastinal lymph node dissection for solitary
lung nodule was also done (January 2010). On tumor-node-meta-
stases staging, the patient was pT1aN0M0 (stage 1B) and it was
consistent with a well-differentiated adenocarcinoma. The patient
was discharged from the hospital without any early post-operative
complications. She started taking an aromatase inhibitor (Letrozole
®
2.5 mg daily, Femara, Novartis, Basel, Switzerland). In the 4 month
follow-up of our patient, she had no clinical, biochemical or
radiological evidence of recurrence disease or distant metastases.
Her current general condition is satisfactory without any post-
operative complications. However, long-term follow-up is required
for assessment of disease recurrence and distant metastases.
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Fig. 1. Original mass from a myomectomy specimen composed of
benign looking spindle cells (H&E, 200).
Fig. 2. Lymph node metastasis (para-aortic lymph node) (H&E,
100).Discussion
BML is a relatively rare disease. It is considered to be benign
histologically, but it occasionally metastasizes to distant sites such as
lung, heart, inferior vena cava, retroperitoneal lymph nodes, mu-
scles, and the bone (clinically malignant).
BML is usually characterized by uterine leiomyoma in young
adulthood, with pulmonary metastasis occurring in the premeno-
pausal period. Kayser et al. [4] reported that the mean interval
between hysterectomy and the development of lung lesions was
24.9 years. Primary lung tumor in this case was incidentally detected
on an imaging study, but since BML is known have metastases to
lung most frequently, it is necessary to make a precise lung assess-
ment during clinical follow up. There are a handful of reports about
lymph node metastasis in BML. However, multiple pelvic and para-
aortic lymph node metastases such as were present in this case are
quite rare. Here, the authors report this rare case.
For an extrauterine lesion, a leiomyosarcoma has to be excluded.
Pathologic and immunohistochemical studies to exclude other
neoplasms are essential, especially when the metastatic site is un-
common. The metastatic potential of BML is not completely esta-
blished. Previously reported cases of BML have included low-grade
endometrial stromal sarcoma, which may play a significant role in
the metastasis of benign uterine tumors. However some research
using genetic analyses showed BML to be clonally derived from
benign-appearing uterine leiomyomas [2].
There is no standard treatment guideline for BML currently.
Reported treatment modalities include careful observation, surgical
resection, hysterectomy and bilateral oophorectomy, progestins, aro-
matase inhibitor, and medical castration using luteinizing hormone-
releasing hormone analogues [5]. A radical surgical resection, if
possible, has been advocated as the primary treatment. Hormonal
therapy has been suggested as the best option for unresectable me-
tastatic disease. The rationale for the use of hormonal therapy is
based on the presence of estrogen and progesterone receptors in
both the primary tumor as well as in the metastatic tumors. Clinical
evidence of a hormonal influence was supported by the fact that the
pulmonary nodules diminish in size following menopause, during
pregnancy and after the withdrawal of hormonal contraception. This
is further supported by the beneficial effects of bilateral oophorec-
tomy [6]. Depending on the locations of the metastases and the
hormone receptor status, we believe that treatment should be
individualized for each patient.
Long-term close surveillance is required in a BML patient for
early detection of disease recurrence or distant metastases. Because
of the limited therapeutic options, new drugs or new therapeutic mo-
dalities should be considered. In the future, studies with long-term
follow-up may be helpful for their implication in clinical practice. 
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